ALEC Alector, Inc.

NASDAQ
$1.96

Alector, Inc. (ALEC) is expected to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $0.24 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +6.5% since its last earnings release on August 6, 2026.

Alector Beat Consensus Estimates
Thursday, August 6, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · 4:05 PM ET
Earnings Whisper
-
vs ($0.24)
Rev est $870K
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.01

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Alector, Inc.

Alector Inc. is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Its product portfolio includes AL001, AL101, Al002 and AL003 which are in clinical stage. Alector Inc. is headquartered in South San Francisco, California.

Sector

Healthcare

Industry

Biotechnology